Skip to main content

Market access for medical technologies in Italy

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Italy

dfghjk

Key topics

There are two key themes describing market access for medical technologies in Italy:

  • Reimbursement: payment mechanism via DRG system, add-on reimbursement 
  • Health technology assessment: assessments by national and regional HTA organizations
     
ghj

Reimbursement

Reimbursement of hospital care in Italy depends on the “ownership” status of hospitals and includes diagnosis-related group (DRG) and global budget mechanisms. 

Reimbursement of the hospital activity is made solely through a diagnosis-related group (DRG) system. Italy does not have its own system and adopted the CMS DRG version 24. The system is very rigid at the national level, with no updates made since the adoption of the DRG system. 

DRGs are determined by the combination of a procedure code and a diagnosis code (ICD-9-CM from the 2007 year). Procedure codes have not been updated since 2007, and many innovative technologies cannot be appropriately coded in the Italian system.

Regions can establish their own tariffs and can innovate on the structure of the DRG system. This includes the creation of DRG sub-categories (DRG split mechanism) or add-on reimbursement for expensive procedures or devices. 

cvbn

Health technology assessment

HTAs are performed at the national level by AGENAS and in several regions. In early 2024, the National HTA Program for Medical Devices became fully functional with the initiation of the first evaluations of technologies.

1111

Specifics for IVD tests

In-vitro diagnostic tests are reimbursed using a fee-for-service mechanism via the regional reimbursement catalogs (using an adaptation of ICD-9-CM classification) in outpatient settings.

MTRC has experience with more than 262 projects in Italy

News and insights

Italy Starts the Operational Phase of the 2026–2028 National HTA Program for Medical Devices

In January 2026, Italy entered the operational phase of the 2026–2028 National Health Technology Assessment Program for Medical Devices (PNHTA-DM) following the release of approximately €13 million from the national medical device governance fund. Coordinated by the National Agency for Regional Health Services (AGENAS), the program strengthens Italy’s national HTA system that will impact market access and procurement decisions for medical technologies.

Rapid HTAs of seven medical devices released in Tuscany in December 2025

In December 2025, the HTA body of Tuscany Regional Healthcare published seven new rapid HTA reports on medical devices in cardiovascular, neurosurgery, neuromodulation, orthopedics, urology, and surgical fields.

Healthcare measures implemented within the 2026 Budget Law in Italy

In January 2026, the Budget Law 2026 entered into force in Italy, introducing healthcare-related measures, including provisions for National Health Fund financing, increased budgets for recruiting healthcare personnel, initiatives supporting prevention, research, as well as investments in regional healthcare services and digitalization.

Get in touch

Contact us to discuss your needs and learn about our services